MZ appoints team for in vitro program

The Team consists of:

1) Chairperson - Dagmara Korbasinska - representative of the Ministry of Health;

2) Prof. Mariusz Bidzinski, MD - national consultant in gynecologic oncology, head of the Gynecologic Oncology Clinic at the Maria SklodowskaCurie National Institute of Oncology - National Research Institute;

3) Prof. Robert Zygmunt Spaczyński, MD - national consultant in gynecological and reproductive endocrinology;

4) Prof. Miroslaw Wielgoś, MD - national consultant in perinatology;

5) Prof. Rafał Kurzawa, MD - President of the Polish Society for Reproductive Medicine and Embryology;

6) Prof. CMKP Michal Ciebiera, MD, PhD - Director of the Warsaw Institute of Women's Health, Acting Head of Clinic II Department of Obstetrics and Gynecology at the Medical Center for Postgraduate Education;

7) Dr. Damian Warzecha, M.D. - head of the Gynecology and Obstetrics Department of the Warsaw Southern Hospital Ltd;

8) Marta Górna - representative of the Association for Infertility Treatment and Adoption Support "Our Stork";

9) Dr. Joanna Kufel-Grabowska, M.D. - chairman of the Section on Fertility in Cancer of the Polish Cancer Society;

10) Prof. Krzysztof Łukaszuk, MD - Medical University of Gdańsk;

11) Professor Michał Radwan, MD - Chairman of the Fertility and Infertility Section of the Polish Society of Gynecologists and Obstetricians;

12) a representative of the Agency for Health Technology Assessment and Tarification;

13) A representative of the Treatment Department at the Ministry of Health;

14) Secretary - a representative of the Department of Public Health at the Ministry of Health.

The tasks of the Team are to develop criteria for the health policy program for the financing of infertility treatment by means of in vitro fertilization, referred to in Article 48a paragraph 16a of the Act of August 27, 2004 on health care services financed from public funds, hereinafter referred to as "the program", including in particular:

1) the criteria for the inclusion of the couple in the program and the criteria for the exclusion of the couple from the program, taking into account, in particular, the age of the woman at which the highest efficiency of the in vitro fertilization procedure can be achieved and other necessary conditions;

2) criteria for selecting program implementers;

3) medical assumptions for the in vitro fertilization procedure, including, in particular, the scope of the procedure and the number of in vitro fertilization cycles performed for the couple;

4) the rules for financing individual infertility treatment procedures and drugs under the program;

5) assumptions for securing fertility for the future, as referred to in Article 10 of the Act of June 25, 2015 on Infertility Treatment (Journal of Laws of 2020, item 442).

Source: OJ MZ